Acute Porphyria Drug Database

C01EB17 - Ivabradine
Propably not porphyrinogenic
PNP

Rationale
Ivabradine is not an inhibitor or an inducer of CYP3A4.
Therapeutic characteristics
Ivabradine is indicated for the treatment of coronary artery disease, for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and for the treatment of chronic heart failure. Common side effects are headache and dizziness.
Metabolism and pharmacokinetics
Under physiological conditions ivabradine is highly water-soluble and is extensively metabolised by CYP3A4. The major active metabolite is N-desmethyl-ivabradine (S 18982) which is also metabolised by CYP3A4 (SPC). The half-life elimination of ivabradine is 2 hours in plasma and the effective half-life is 11 hours. Ivabradine has low affinity for CYP3A4 and are therefore a very weak inhibitor of CYP3A4 (SPC). Both in vitro and in vivo data have shown that it is unlikely to influence the pharmacokinetics and pharmacodynamics of other CYP3A4 substrates (Portolés 2006 and SPC). No drug-drug interactions with ivabradine as a perpetrator are observed (Interaksjoner and Interaktionsdatabasen), which indicate that ivabradine is not an inhibitor or inducer of CYP enzymes. The summary of product characteristics states that a specific drug-drug interaction study has shown that ivabradine does not have a clinical significant effect on the pharmacokinetics of simvastatin, a CYP3A4 substrate. This also indicates that ivabradine is not an inhibitor or an inducer of CYP3A4.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

References

  1. Scientific articles
  2. Portolés A, Calvo A, et al. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. J Clin Pharmacol. 2006 Oct;46(10):1195-203. PMID 16988209. #1038
  3. Drug interaction databases
  4. Interaksjoner. ivabradine #1228
  5. Interaktionsdatabasen. ivabradine #1229
  6. Summary of Product Characteristics
  7. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Ivabradine. Last edition: 10.2012 #1230

Similar drugs
Explore alternative drugs in similar therapeutic classes C01E / C01EB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙